Section of Hematology & Immunology
Mission Statement
Our focus is to test newly developed drugs in the immunologic and coagulation field.
We try to combine in vitro, ex vivo and in vivo trials to obtain an integrated insight into pathophysiologic processes.
Current Projects
- First in man trials with chemokines, cytokines, antibodies
- Biosimilarity trials with biologicals
- Phase I/II drug trials in LPS model to measure pharmacodynamics of novel compounds under standardized conditions of inflammation in healthy volunteers.
- Phase I trials in LPS lung instillation model
- Phase I-III patient trials, to monitor immunmodulation and coagulation in various diseases including stroke.
- Target on vessels, platelets and coagulation: Platelet hyperfunction in myocardial infarction, thrombotic microangiopathies, critically ill, extracorporeal circulations (hemodialysis, cardiopulmonary bypass, extracorporeal membrane oxygenation, left ventricular assist devices)
Key Publications
1. Schoergenhofer C, Hobl EL, Schellongowski P, Heinz G, Speidl WS, Siller-Matula JM, Schmid M, Sunder-Plaßmann R, Stimpfl T, Hackl M, Jilma B: Clopidogrel in Critically Ill Patients . Clin Pharmacol ther 2018 Feb; 103(2):217-223
2. Schwameis M, Kündig T, Huber G, von Bidder L, Meinel L, Weisser R, Aberer E, Härter G, Weinke T, Jelinek T, Fätkenheuer G, Wollina U, Burchard GD, Aschoff R, Nischik R, Sattler G, Popp G, Lotte W, Wiechert D, Eder G, Maus O, Staubach-Renz P, Gräfe A, Geigenberger V, Naudts I, Sebastian M, Reider N, Weber R, Heckmann M, Reisinger EC, Klein G, Wantzen J, Jilma B: Topical azithromycin for the prevention of Lyme borreliosis: a randomised, placebo-controlled, phase 3 efficacy trial. Lancet Infect Dis. 2017 Mar; 17(3):322-329. doi: 10.1016/S1473-3099(16)30529-1 Protocol
3. Schwameis M, Roppenser B, Firbas C, Gruener CS, Model N, Stich N, Roetzer A, Buchtele N, Jilma B, Eibl MM: Safety, tolerability, and immunogenicity of a recombinant toxic shock syndrome toxin (rTSST)-1 variant vaccine: a randomised, double-blinde, adjuvant-controlled, dose escalation first-in-man trial. Lancet Infect Dis. 2016 Jun 10. pii: S1473-3099(16)30115-3
4. Peyvandi F, Sully M, Kremer Hovinga JA, Cataland S, Knöbl P, Wu H, Artoni W, Westwood JP, Mansouri Taleghani M, Jilma B, Callewaert F, Ulrichs H, Duby C, Tersago D; TITAN Investigators. Caplacizumab for Acquired Thrombotic Thrombozytopenic Purpura. N Engl J Med. 2016 Feb 11;374(6):511-522.
5. Ramsauer K, Schwameis M, Firbas C, Müllner M, Putnak RJ, Thomas SJ, Desprès P, Tauber E, Jilma B, Tangy F: Immunogenicity, safety, and tolerability of a recombinant measles-virus-based chikungunya vaccine: a randomised, double-blind, placebo-controlled, active-comparator, first-in-man trial. Lancet Infect Dis. 2015 Feb 27. pii:S1473-3099(15)70043-5
6. Hobl EL, Stimpfl T, Ebner J, Schörgenhofer C, Derhaschnig U, Sunder-Plassmann R, Jilma-Stohlawetz P, Mannharter C, Posch M, Jilma B: Morphine decreases clopidogrel concentrations and effects: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol. 2014 Feb 25;63(7):630-5 (Award by American Heart Association)
7. Siller-Matula J, Lang IM, Christ G, Jilma B: Calcium-Channel Blockers Reduce the Antiplatelet Effect of Clopidogrel. J Am Coll Cardiol 2008, 52:1557-63 (Award by the Austrian Society of Cardiology)
For information please contact our Section Head:
Bernd Jilma, MD
E-Mail: bernd.jilma@meduniwien.ac.at
Quick Links
Featured
